AbCellera Biologics Inc. ABCL Deferred Foreign Income Tax Expense Benefit
Deferred Foreign Income Tax Expense Benefit at other companies
Other financials
Where this comes from
Reported directly by AbCellera Biologics Inc. in its filing.
Tagged under the XBRL concept us-gaap:DeferredForeignIncomeTaxExpenseBenefit.
The official record: AbCellera Biologics Inc.’s 10-K, filed February 24, 2026, on SEC EDGAR. View the filing →
Ask your AI about AbCellera Biologics Inc.'s deferred foreign income tax expense benefit.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is AbCellera Biologics Inc.'s deferred foreign income tax expense benefit?
- AbCellera Biologics Inc. (ABCL) reported deferred foreign income tax expense benefit of -$234.5K in Q4 2025.
- How has AbCellera Biologics Inc.'s deferred foreign income tax expense benefit changed year-over-year?
- AbCellera Biologics Inc.'s deferred foreign income tax expense benefit increased by 95.4% year-over-year, from -$5.12M to -$234.5K.
- What is the long-term trend for AbCellera Biologics Inc.'s deferred foreign income tax expense benefit?
- Over 2 years (2023 to 2025), AbCellera Biologics Inc.'s deferred foreign income tax expense benefit has grown at a -39.5% compound annual growth rate (CAGR), from -$2.57M to -$938K.
- What does deferred foreign income tax expense benefit mean?
- Reflects the change in deferred tax assets or liabilities related to foreign jurisdictions resulting from temporary differences in tax and financial reporting bases. It provides insight into the company's future tax liabilities or potential tax savings in international markets.